MedTrace Logo

Tranexamic Acid in Functional Endoscopic Sinus Surgery

NCT05686005 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2023-05-03

No results posted yet for this study

Summary

The purpose of the study is to compare the effect of oral tranexamic acid vs. intravenous in decreasing bleeding and improving the field during FESS.

Conditions

  • Anesthesia

Interventions

DRUG

Oral tranexamic acid

4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.

DRUG

Intravenous tranexamic acid

15mg/kg of tranexamic acid in a 20ml syringe slowly intravenous during induction.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-03
Primary Completion
2023-04-29
Completion
2023-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05686005 on ClinicalTrials.gov